Overview

A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, randomized controlled trial to determine the effects of Telacebec (Q203) on inhibition of leukotriene production, clinical change, pharmacokinetics, and safety in participants with moderate COVID-19 disease
Phase:
Phase 2
Details
Lead Sponsor:
Qurient Co., Ltd.